How much revenue does Scopus BioPharma make?

Scopus BioPharma reported $0 in revenue for fiscal year 2022. In Q2 2023 revenue was $0.

What companies are similar to Scopus BioPharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bloomios, Inc. (BLMS), Quick-Med Technologies, Inc. (QMDT), Viropro Inc. (VPRO), Arev Life Sciences Global Corp. (AREVF).

Scopus BioPharma Inc. (SCPS) Stock

About Scopus BioPharma Inc.

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3si...

At a glance

Scopus BioPharma reported revenue of $0 for fiscal year 2022, and net income of -$11.61 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.